National Health (Price and Special Patient Contribution) Amendment Determination 2014 (No. 2) (No. PB 18 of 2014) (Cth)

PB 18 of 2014

National Health (Price and Special Patient Contribution) Amendment Determination 2014 (No. 2)

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated 21 March 2014

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health

1          Name of Instrument

(1)        This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2014 (No. 2).

(2)        This Instrument may also be cited as PB 18 of 2014.

2          Commencement

This Instrument commences on 1 April 2014.

3          Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1     Amendments

1. Schedule 1, entry for Carbomer

(a)   omit from the column headed “Determined Price”:             3.12        substitute:             2.62

(b)   omit from the column headed “Claimed Price”:                  4.32        substitute:             4.11

1. Schedule 1, after entry for Carbomer

insert:

Carmellose	Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Cellufresh	1	6.71	7.99
Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Celluvisc	1	6.71	7.99

1. Schedule 1, entry for Clarithromycin

omit from the column headed “Claimed Price”:          4.36      substitute:             5.87

1. Schedule 1, entry for Dexamethasone with Framycetin and Gramicidin

(a)   omit from the column headed “Determined Price”:             2.40        substitute:             2.85

(b)   omit from the column headed “Claimed Price”:                  3.94        substitute:             4.39

1. Schedule 1, entry for Eprosartan in the form Tablet 400 mg (as mesylate)

omit from the column headed “Claimed Price”:          6.95        substitute:             7.16

1. Schedule 1, entry for Eprosartan in the form Tablet 600 mg (as mesylate)

omit from the column headed “Claimed Price”:          15.77     substitute:             17.23

1. Schedule 1, entry for Metoclopramide

(a)   omit from the column headed “Determined Price”:             1.44        substitute:             1.21

(b)   omit from the column headed “Claimed Price”:                  3.88        substitute:             3.26

1. Schedule 1, entry for Prednisolone in the form Tablet 1 mg

omit from the column headed “Claimed Price”:          1.90        substitute:             2.20

1. Schedule 1, entry for Prednisone

omit from the column headed “Claimed Price”:          2.46        substitute:             2.71

1. Schedule 1, entry for Trandolapril in the form Capsule 500 micrograms

omit from the column headed “Claimed Price”:          2.57        substitute:             4.40

1. Schedule 1, entry for Trandolapril in the form Capsule 1 mg

omit from the column headed “Claimed Price”:          5.19        substitute:             6.98

1. Schedule 1, entry for Trandolapril in the form Capsule 2 mg

omit from the column headed “Claimed Price”:          7.20        substitute:             7.85

1. Schedule 1, entry for Trandolapril in the form Capsule 4 mg

omit from the column headed “Claimed Price”:          11.60     substitute:             12.25

1. Schedule 1, entry for Verapamil in the form Tablet containing verapamil hydrochloride 40 mg

omit from the column headed “Claimed Price”:          4.50        substitute:             6.74

1. Schedule 1, entry for Verapamil in the form Tablet containing verapamil hydrochloride 80 mg

omit from the column headed “Claimed Price”:          7.52        substitute:             9.77